Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845429 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 729
- Enrollment target
NCT00845429 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 729 participants.
The verdict
NCT00845429, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 729 participants
- Enrollment target
Study Summary
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Interventions
- BIOLOGICAL Influenza virus vaccine - cell based (2007-2008 Formulation)
- BIOLOGICAL Influenza virus vaccine - cell-based (2007-2008 Formulation)
- BIOLOGICAL Influenza virus vaccine (2007-2008 Formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845429
The ClinicalTrials.gov registry entry for NCT00845429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 729 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Influenza virus vaccine - cell based (2007-2008 Formulation) is the first listed.
NCT00845429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845429 about?
NCT00845429 is a clinical study titled "Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects". Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational ce...
What is the current status of trial NCT00845429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 729 participants. The study started on 2007-10. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00845429?
The interventions under investigation include: Influenza virus vaccine - cell based (2007-2008 Formulation) (BIOLOGICAL), Influenza virus vaccine - cell-based (2007-2008 Formulation) (BIOLOGICAL), Influenza virus vaccine (2007-2008 Formulation) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00845429?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.